TEEC CHEE biotechnology GMP cell culture production line officially put into operation, accelerating the local biomedical sector innovation

From biologics to vaccines, from gene therapy to cell therapy, every aspect of biopharmaceuticals relies on a core raw material——cell culture medium. For years, China's cell culture medium market has been dominated by imported products, with supply chain stability and price control remaining critical challenges for the industry.

The official commissioning of TEEC CHEE Biotechnology's latest GMP cell culture medium production line marks a significant step forward for China in the field of key raw materials for biomedicine. This production line, built to international standards, will provide high-quality, customized culture medium solutions for China's biopharmaceutical enterprises.

01 The invisible pillar of biomedicine

Cell culture medium is the "chip" in the biomedical field, known as the "blood of life". Any biological preparation products that need to be produced with cells can not be separated from the support of cell culture medium.

In the biopharmaceutical industry, there's a popular analogy: cell culture medium is like infant formula, directly impacting the healthy development of biological drugs – this "infant" in the field. With the rapid growth and expansion of the biopharmaceutical sector, the market size for cell culture media is projected to exceed 10 billion yuan in the coming years.

However, it is an undeniable fact that China consumes a large amount of cell culture medium every year, but the domestic market has long been dominated by imported brands, and the share of domestic brands has been low for a long time. This dependence not only increases production costs, but also brings uncertainty to the security of the biomedical industry chain.

Teeechee Biotechnology's GMP cell culture production line is aimed at this "bottleneck" problem. Through continuous research and innovation, the company has achieved commercialization of its products, providing more options for domestic biopharmaceutical enterprises.

02 Technical breakthrough: from general to precise

Cell culture medium is not a new thing, but there are many bottlenecks between research and development and industrial transformation. Especially to achieve the leap from "usable" to "good use", it requires profound technical accumulation and continuous process optimization.

TEEC CHEE Biotechnology's production lines can produce both liquid and powder culture media. The liquid culture line has an annual output of more than 200,000 liters, while the powder culture line has an annual output of more than 60 tons.

In terms of culture medium types, TEEC CHEE not only provides classic basic culture media such as DMEM and RPMI1640, but also develops special culture media for specific cell types and experimental needs.

For example, the classic DMEM medium is derived from Dulbecco's modified Eagle medium (DMEM), which itself was improved from MEM medium. Originally designed for mouse fibroblasts, it contains twice the amino acid concentration and four times the vitamin content of MEM. The doubled concentrations of HCO3⁻ and CO₂ provide enhanced buffering capacity.

RPMI1640, as another common basic culture medium, is widely used in the culture of immune cells and tumor cells because of its relatively simple composition and applicability to a variety of mammalian cells.

03 Quality system: international standards to build reliable products

Quality is the lifeblood of cell culture products. TEEC CHEE Biotechnology builds a quality system in strict accordance with international standards to ensure batch consistency and reliability of products.

The quality management system covers the entire process from raw material procurement to production release. All materials undergo rigorous screening and supplier audits to ensure traceable origins and controlled quality. Production strictly adheres to Good Manufacturing Practice (GMP) standards, guaranteeing each batch meets stringent quality requirements.

In terms of quality control, the company implements a number of quality tests on products, including clarity, pH value, endotoxin content, sterility test (bacteria, fungi, mycoplasma) and cell growth test, to ensure that the products meet the needs of scientific research and industrial production.

04 Responding to market challenges: from customization to stable supply

The rapid development of the biopharmaceutical industry has put forward higher requirements for cell culture medium. Different biological drugs require different cell culture processes, and the demand for culture medium is increasingly diversified.

With rich formula experience and technical knowledge, TEEC CHEE Biotechnology can produce high quality customized cell culture media and innovative solutions according to customers' specific needs. Customization service has become one of the core competencies of the company.

In addition to standardized products, the company can also customize dry powder cell culture medium for customers, and provide customized services and operational support to help biopharmaceutical companies optimize process flow and shorten product time to market.

Future layout of culture medium: continuous innovation and industrial integration

For TEEC CHEE Biotechnology, the successful launch of the GMP cell culture medium production line is just the beginning. The company plans to continue to launch a variety of high-performance cell culture media and cell culture derivatives and other regenerative medicine products and customized development services.

With the rise of cutting-edge fields such as cell and gene therapy, organoid models, and related technologies, there is a growing demand for specialized culture media. For instance, innovative products like tumor organoid culture media enable researchers to better simulate diseases and predict patients' responses to treatments, thereby improving the success rate of drug development.

TEEC CHEE Biotechnology is actively laying out these emerging fields, and through continuous R&D investment, it is driving the leapfrog development of China's biomedical industry from catching up to running side by side, and then leading the race.

The cell culture medium market segment is entering a golden age of growth, driven by the rapid expansion of the biopharmaceutical industry. The demand for cell culture media supporting biological production and advanced therapies is projected to grow at a compound annual growth rate (CAGR) of 10-12% through 2031.

The launch of Teeechee Biotech's production line is just the beginning. In the coming years, the company plans to further expand its production capacity and enrich its product line to provide more comprehensive and efficient culture medium solutions for domestic biomedical enterprises.